Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal

Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.